Intramural thrombosis is a consistent finding in the arteries of patients who die following
coronary angioplasty. This thrombosis is thought to have a role in restonosis, which is a
common complication of coronary angioplasty. It has been hypothesised that antithrombotics
such as hirudin or tissue-type plasminogen activator (tPA), may be therapeutically useful
following angioplasty. This report describes the bioavailability of both agents following
subcutaneous (sc) injection in cholesterol-fed rabbits. Intravenously delivered tPA has a half …